2. Immunology/Inflammation Apoptosis
  3. Toll-like Receptor (TLR) Apoptosis NO Synthase
  4. ODN 1826 sodium

ODN 1826 sodium  (Synonyms: CpG 1826 sodium)

Cat. No.: HY-146245C Purity: 99.51%
COA
SDS
Handling Instructions Technical Support

ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma.

For research use only. We do not sell to patients.

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of ODN 1826 sodium:

ODN 1826 sodium Related Antibodies

Top Publications Citing Use of Products

    ODN 1826 sodium purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Sep 1:e02375.  [Abstract]

    ODN 1826 (CpG, 500 ng per well; 24 h) significantly promoted the repolarization of M2-typed bone marrow-derived cells (BMDM), which stood for tumor-associated macrophages (TAM), with a significant increase of M1 (iNOS) and a decrease of M2 markers (Fizz1 and Mrc1).

    ODN 1826 sodium purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Aug 29:380:123930.  [Abstract]

    Cytotoxicity analysis of DC 2.4 cells treated with DNA-OprF/PcrV + CpG (ODN 1826) for 24 h. CpG was functionally integrated with the DNA vaccine via physical mixing. Specifically, 10 μg of pVAX1-OprF, 10 μg of pVAX1-PcrV, and 10 μg of CpG ODN were vortex-mixed in 150 μl of 1640 medium, followed by the addition of 60 μl of transfection reagent (mass-to-volume ratio = 1:2). The mixture was incubated at room temperature for 30 min to form transfection complexes, sterilized by passage through a 0.22 μm filter, and used immediately.

    ODN 1826 sodium purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Aug 29:380:123930.  [Abstract]

    ODN 1826 (CpG, 0.1 μg/μL; s.c.; 200 μL injected every 2 weeks for a total of three times).
    HE-stained image of pathological sections of the heart, liver, lung, and kidney after immunization (100×). Scale bar = 50 μm. These results revealed no obvious tissue pathological changes or inflammatory cell infiltration in the four treatment groups, including the DNA-OprF/PcrV + CpG group.

    ODN 1826 sodium purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2025 Sep 5;50(5):288.  [Abstract]

    ODN 1826 (CpG) regulate astrocyte cell viability and TLR9/NF-κB pathway activation. Human astrocytes were treated with varying concentrations of CpG oligodeoxynucleotides (0, 100, 1000, and 5000 ng/mL) for 24 h. Cell viability was assessed using CCK-8 assay.

    ODN 1826 sodium purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2025 Sep 5;50(5):288.  [Abstract]

    ODN 1826 (CpG) regulate astrocyte cell viability and TLR9/NF-κB pathway activation. Human astrocytes were treated with varying concentrations of CpG oligodeoxynucleotides (0, 100, 1000, and 5000 ng/mL) for 24 h. Apoptosis rates were determined by flow cytometry analysis using Annexin V-FITC and propidium iodide staining.

    ODN 1826 sodium purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2025 Sep 5;50(5):288.  [Abstract]

    ODN 1826 (CpG) regulate astrocyte cell viability and TLR9/NF-κB pathway activation. Human astrocytes were treated with varying concentrations of CpG oligodeoxynucleotides (0, 100, 1000, and 5000 ng/mL) for 24 h. Protein expression levels of TLR9, total NF-κB, and phosphorylated NF-κB (p-NF-κB) were analyzed by Western blot with GAPDH as loading control.

    View All Toll-like Receptor (TLR) Isoform Specific Products:

    View All Isoforms
    TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

    View All NO Synthase Isoform Specific Products:

    View All Isoforms
    nNOS iNOS eNOS

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma[1][2][3][4][5][6].

    IC50 & Target

    TLR9

     

    In Vitro

    ODN 1826 (1 μg/mL; 24 h) sodium induces nitric oxide (NO) and inducible nitric oxide synthase (iNOS) production in RAW 264.7 mouse macrophages[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    ODN 1826 sodium Related Antibodies
    In Vivo

    CpG-1826 (100 μg/tumor; intratumoral injection; every 3 days for up to 4 times) sodium delays the growth of subcutaneously implanted GL261 gliomas in C57BL/6NTac mice, inducing increased infiltration of macrophages and B cells into tumors, with significant growth delay in ~50% of mice[4].
    ODN 1826 (18 nM; s.c.; 3 times a week for 7 weeks) sodium increases aortic atherosclerotic plaque size in a chronic vascular injury mouse model[5].
    ODN 1826 (0.05 mg; i.p.; 1, 3, 5, 8, 11, 13 days) sodium has a strong anti-tumor growth effect in a Lewis lung cancer mouse tumor model[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 6-week-old male C57BL/6NTac mice; GL261 glioma or B16F10 melanoma subcutaneously implanted in posterior flanks[4].
    Dosage: 100 μg/tumor
    Administration: Intratumoral injection; every 3 days for up to 4 treatments
    Result: Slowed tumor growth, increased F4/80+ macrophages and B220+ B cells in tumors, with variable responses (50% mice showed prolonged stasis) (in GL261 glioma model).
    Achieved complete tumor regression and induced long-term immune memory in combination with Cyclophosphamide (HY-17420).
    Delayed growth but did not induce regression, with modest increases in F4/80+ macrophages and B220+ B cells in combination with Cyclophosphamide (in B16F10 melanoma model).
    Molecular Weight

    6364.1 (free acid)

    Appearance

    Solid

    Color

    White to off-white

    SMILES

    [ODN 1826 (sodium)]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    -20°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Purity & Documentation

    Purity: 99.51%

    SDS (251 KB)

    COA (244 KB) LCMS (374 KB)

    Handling Instructions (2242 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    ODN 1826 sodium Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    ODN 1826CpG 1826ODN1826ODN-1826CpG1826CpG-1826Toll-like Receptor (TLR)ApoptosisNO SynthaseNitric oxide synthasesNOSRAW 264.7immunostimulatormurinegliomaLewis lung cancerGL261B16F10 melanomaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ODN 1826 sodium
    Cat. No.:
    HY-146245C
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.